Collegium Pharmaceutical, Inc. delivered a strong second quarter in 2025, achieving record quarterly net revenue of $188.0 million, a 29% increase year-over-year. This growth was primarily driven by record Jornay PM net revenue and solid performance from its pain portfolio. The company also reported robust adjusted EBITDA and significant cash flow generation, leading to an upward revision of its full-year 2025 financial guidance.
Record quarterly net revenue of $188.0 million, marking a 29% increase year-over-year.
Jornay PM net revenue reached a record $32.6 million, with prescriptions growing 23% year-over-year.
Pain portfolio generated $155.4 million in net revenue, up 7% year-over-year, with all three core products showing growth.
Full-year 2025 net revenue guidance was raised to $745 million to $760 million, and adjusted EBITDA guidance to $440 million to $455 million.
Collegium Pharmaceutical has raised its full-year 2025 guidance for net product revenues and adjusted EBITDA, reflecting strong performance in the first half of the year and anticipated continued growth, particularly for Jornay PM.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance